Your session is about to expire
← Back to Search
Other
ANV600 + Pembrolizumab for Solid Tumors
Phase 1 & 2
Recruiting
Research Sponsored by Anaveon AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
Measured or calculated creatinine clearance ≥50 mL/min;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to study the safety, effectiveness, and how the drug ANV600 works in the body when given alone or with pembrolizumab to adults with advanced solid tumors."
Who is the study for?
This trial is for adults over 18 with advanced solid tumors who have a life expectancy of at least 3 months. They must be able to follow the study plan and have certain levels of blood cells and kidney function. People can't join if they are too sick (with an ECOG performance status over 1) or don't meet other health requirements.
What is being tested?
The study is testing ANV600 alone or combined with pembrolizumab in treating advanced solid tumors. It aims to understand how safe these treatments are, how the body processes them, and their effectiveness against cancer.
What are the potential side effects?
Possible side effects include reactions related to the immune system since both drugs work by activating it against cancer. This might lead to inflammation in different parts of the body, fatigue, infusion-related reactions, and changes in blood tests.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My kidneys are functioning well, with a creatinine clearance rate of at least 50 mL/min.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: ANV600 single agentExperimental Treatment1 Intervention
Group II: ANV600 in combination with pembrolizumab (KEYTRUDA®)Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Anaveon AGLead Sponsor
4 Previous Clinical Trials
98 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,032 Previous Clinical Trials
5,189,476 Total Patients Enrolled